Cargando…
Cost effectiveness in treating ventilator-associated pneumonia
Ventilator-associated pneumonia is a common illness in intensive care unit patients. The costs of management are increased when infection involves resistant organisms, as well as unnecessary and prolonged therapy. Efforts at accurate diagnosis, therapy and prevention can reduce the cost impact of th...
Autor principal: | Niederman, Michael S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137281/ https://www.ncbi.nlm.nih.gov/pubmed/11737896 |
Ejemplares similares
-
Ventilator-associated pneumonia
por: Ranzani, Otavio T., et al.
Publicado: (2022) -
Ventilator-associated pneumonia: present understanding and ongoing debates
por: Nair, Girish B., et al.
Publicado: (2014) -
Advancing the science of ventilator-associated pneumonia surveillance
por: Klompas, Michael
Publicado: (2012) -
What COVID-19 Has Taught Us: Ventilator-associated Pneumonia Is Back!
por: Niederman, Michael S.
Publicado: (2022) -
Biological markers and diagnosis of ventilator-associated pneumonia
por: Fagon, Jean-Yves
Publicado: (2011)